News|Articles|October 31, 2024
WCG Randomized 1,600 Participants for RSV Vaccine Trial
Author(s)WCG Clinical
A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.
Related Content
Trending on Applied Clinical Trials Online
1
ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation
2
Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial
3
ACT Brief: Simplifying Trials Through Selective Safety Data, AI-Driven Site Partnerships, and Biopharma Strategic Pivots
4
Beyond Eligibility: Making Trust and Behavioral Readiness Actionable in Clinical Trial Recruitment
5